Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Conditions
Multiple Myeloma, Newly Diagnosed · Multiple Myeloma (MM)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Contact: Principal Investigator (Gayathri Ravi, MD)Colorado Blood Cancer Institute, Denver, Colorado, United States
Contact: Principal Investigator (Henning Schade, MD)University of Iowa, Iowa City, Iowa, United States
Contact: Principal Investigator (Christopher Strouse, MD)University of North Carolina, Chapel Hill, North Carolina, United States
Contact: Principal Investigator (Samuel Rubinstein, MD)Oncology Hematology Care, Cincinnati, Ohio, United States
The Ohio State University- The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
Contact: Principal Investigator (Naresh Bumma, MD)SCRI Oncology Partners, Nashville, Tennessee, United States
Contact: Principal Investigator (Hans Lee, MD)University of Texas Southwestern, Dallas, Texas, United States
Contact: Principal Investigator (Aimaz Afrough, MD)Virginia Oncology Associates, Norfolk, Virginia, United States
Contact: Principal Investigator (Scott Cross, MD)University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States
Contact: Principal Investigator (Timothy Schmidt, MD)Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact: Principal Investigator (Ravi Narra, MD)
Study leads
Henning Schade, MD
Study Chair
Colorado Blood Cancer Institute